PaPE-1 | CAS#2107327-36-4 | Estrogen

MedKoo Cat#: 525459 | Name: PaPE-1

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PaPE-1 is a pathway Preferential Estrogen, activating the extranuclear signaling pathway without activity on the nuclear signaling pathway. PaPE-1 elicited anti-apoptotic effects by inhibiting Aβ-induced caspase activities as well as attenuating apoptotic chromatin condensation, and in these ways, PaPE-1 prevented neuronal cell death. Posttreatment with PaPE-1 also downregulated the Aβ-affected mRNA expression of apoptosis-specific factors, such as Bax, Gsk3b, Fas, and Fasl, except for Bcl2, which was upregulated by PaPE-1.

Chemical Structure

PaPE-1

CAS#2107327-36-4 (S-isomer)

Theoretical Analysis

MedKoo Cat#: 525459

Name: PaPE-1

CAS#: 2107327-36-4 (S-isomer)

Chemical Formula: C17H18O2

Exact Mass: 254.1307

Molecular Weight: 254.33

Elemental Analysis: C, 80.28; H, 7.13; O, 12.58

Price and Availability

Size	Price	Availability
5mg	USD 135.00	Ready to Ship
10mg	USD 250.00	Ready to Ship
25mg	USD 450.00	Ready to Ship
50mg	USD 750.00	Ready to Ship
100mg	USD 1,250.00	Ready to Ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

2107327-36-4 (S-isomer) 2107327-37-5 (R-isomer)

Synonym

PaPE-1; PaPE 1; PaPE1; pathway Preferential Estrogen;

IUPAC/Chemical Name

(S)-5-(4-Hydroxy-3,5-dimethyl-phenyl)-indan-1-ol

InChi Key

UCXWFKNKSWDWCD-INIZCTEOSA-N

InChi Code

InChI=1S/C17H18O2/c1-10-7-14(8-11(2)17(10)19)12-3-5-15-13(9-12)4-6-16(15)18/h3,5,7-9,16,18-19H,4,6H2,1-2H3/t16-/m0/s1

SMILES Code

O[C@H]1CCC2=C1C=CC(C3=CC(C)=C(O)C(C)=C3)=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Alzheimer's disease (AD) is a multifactorial and severe neurodegenerative disorder characterized by progressive memory decline, the presence of Aβ plaques and tau tangles, brain atrophy, and neuronal loss. Available therapies provide moderate symptomatic relief but do not alter disease progression.

Product Data

Product Data

Instruction

View handling instruction

Biological target:

PaPE-1 activates the extranuclear signaling pathway without activating the nuclear signaling pathway. PaPE-1 bound 50,000-fold less well to ERα and Erβ estrogen receptors. PaPE-1 activated extranuclear-initiated ER-regulated genes, but showed essentially no activation of nuclear-initiated estrogen receptor (ER) gene targets such as the progesterone receptor.

In vitro activity:

PaPE-1 is a potential therapy that targets non-nuclear ERs for Alzheimer's disease (AD). In a cellular model of AD, PaPE-1 reduced Aβ-induced neurotoxicity, oxidative stress, and apoptosis. While its role in controlling the external apoptotic pathway is debated, PaPE-1 notably restored mitochondrial function, suggesting its anti-AD mechanism primarily targets mitochondrial apoptosis. Reference: Neurotox Res. 2020 Dec;38(4):957-966. https://pubmed.ncbi.nlm.nih.gov/33025361/

In vivo activity:

In a mouse Alzheimer's disease (AD) model, PaPE-1 posttreatment reduced neurodegeneration, restored neurite growth, and inhibited AD-related gene expression. Following 24 h of exposure, PaPE-1 inhibited Aβ-evoked effects, demonstrated by reduced parameters of neurotoxicity, oxidative stress, and apoptosis. Reference: Mol Neurobiol. 2023 Dec 8. doi: 10.1007/s12035-023-03819-5. https://pubmed.ncbi.nlm.nih.gov/38064105/

Preparing Stock Solutions

The following data is based on the product molecular weight 254.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wnuk A, Przepiórska K, Rzemieniec J, Pietrzak B, Kajta M. Selective Targeting of Non-nuclear Estrogen Receptors with PaPE-1 as a New Treatment Strategy for Alzheimer's Disease. Neurotox Res. 2020 Dec;38(4):957-966. doi: 10.1007/s12640-020-00289-8. Epub 2020 Oct 6. PMID: 33025361; PMCID: PMC7591444. 2. Madak-Erdogan Z, Band S, Zhao YC, Smith BP, Kulkoyluoglu-Cotul E, Zuo Q, Santaliz Casiano A, Wrobel K, Rossi G, Smith RL, Kim SH, Katzenellenbogen JA, Johnson ML, Patel M, Marino N, Storniolo AMV, Flaws JA. Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling. Cancer Res. 2019 May 15;79(10):2494-2510. doi: 10.1158/0008-5472.CAN-18-2849. Epub 2019 Mar 12. PMID: 30862719. 3. Pietrzak-Wawrzyńska BA, Wnuk A, Przepiórska-Drońska K, Łach A, Kajta M. Posttreatment with PaPE-1 Protects from Aβ-Induced Neurodegeneration Through Inhibiting the Expression of Alzheimer's Disease-Related Genes and Apoptosis Process That Involves Enhanced DNA Methylation of Specific Genes. Mol Neurobiol. 2023 Dec 8. doi: 10.1007/s12035-023-03819-5. Epub ahead of print. PMID: 38064105. 4. Wnuk A, Przepiórska K, Pietrzak BA, Kajta M. Posttreatment Strategy Against Hypoxia and Ischemia Based on Selective Targeting of Nonnuclear Estrogen Receptors with PaPE-1. Neurotox Res. 2021 Dec;39(6):2029-2041. doi: 10.1007/s12640-021-00441-y. Epub 2021 Nov 19. PMID: 34797527; PMCID: PMC8639538.

In vitro protocol:

In vivo protocol:

1. Pietrzak-Wawrzyńska BA, Wnuk A, Przepiórska-Drońska K, Łach A, Kajta M. Posttreatment with PaPE-1 Protects from Aβ-Induced Neurodegeneration Through Inhibiting the Expression of Alzheimer's Disease-Related Genes and Apoptosis Process That Involves Enhanced DNA Methylation of Specific Genes. Mol Neurobiol. 2023 Dec 8. doi: 10.1007/s12035-023-03819-5. Epub ahead of print. PMID: 38064105. 2. Wnuk A, Przepiórska K, Pietrzak BA, Kajta M. Posttreatment Strategy Against Hypoxia and Ischemia Based on Selective Targeting of Nonnuclear Estrogen Receptors with PaPE-1. Neurotox Res. 2021 Dec;39(6):2029-2041. doi: 10.1007/s12640-021-00441-y. Epub 2021 Nov 19. PMID: 34797527; PMCID: PMC8639538.

1: Pietrzak-Wawrzyńska BA, Wnuk A, Przepiórska-Drońska K, Łach A, Kajta M. Posttreatment with PaPE-1 Protects from Aβ-Induced Neurodegeneration Through Inhibiting the Expression of Alzheimer's Disease-Related Genes and Apoptosis Process That Involves Enhanced DNA Methylation of Specific Genes. Mol Neurobiol. 2023 Dec 8. doi: 10.1007/s12035-023-03819-5. Epub ahead of print. PMID: 38064105. 2: Wnuk A, Przepiórska K, Pietrzak BA, Kajta M. Posttreatment Strategy Against Hypoxia and Ischemia Based on Selective Targeting of Nonnuclear Estrogen Receptors with PaPE-1. Neurotox Res. 2021 Dec;39(6):2029-2041. doi: 10.1007/s12640-021-00441-y. Epub 2021 Nov 19. PMID: 34797527; PMCID: PMC8639538. 3: Zuo Q, Chen KL, Arredondo Eve A, Liu YJ, Kim SH, Katzenellenbogen BS, Katzenellenbogen JA, Madak-Erdogan Z. Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets. Nutrients. 2021 Sep 23;13(10):3334. doi: 10.3390/nu13103334. PMID: 34684335; PMCID: PMC8540756. 4: Marroqui L, Martinez-Pinna J, Castellano-Muñoz M, Dos Santos RS, Medina-Gali RM, Soriano S, Quesada I, Gustafsson JA, Encinar JA, Nadal A. Bisphenol-S and Bisphenol-F alter mouse pancreatic β-cell ion channel expression and activity and insulin release through an estrogen receptor ERβ mediated pathway. Chemosphere. 2021 Feb;265:129051. doi: 10.1016/j.chemosphere.2020.129051. Epub 2020 Nov 20. PMID: 33250229. 5: Wnuk A, Przepiórska K, Rzemieniec J, Pietrzak B, Kajta M. Selective Targeting of Non-nuclear Estrogen Receptors with PaPE-1 as a New Treatment Strategy for Alzheimer's Disease. Neurotox Res. 2020 Dec;38(4):957-966. doi: 10.1007/s12640-020-00289-8. Epub 2020 Oct 6. PMID: 33025361; PMCID: PMC7591444. 6: Madak-Erdogan Z, Band S, Zhao YC, Smith BP, Kulkoyluoglu-Cotul E, Zuo Q, Santaliz Casiano A, Wrobel K, Rossi G, Smith RL, Kim SH, Katzenellenbogen JA, Johnson ML, Patel M, Marino N, Storniolo AMV, Flaws JA. Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling. Cancer Res. 2019 May 15;79(10):2494-2510. doi: 10.1158/0008-5472.CAN-18-2849. Epub 2019 Mar 12. PMID: 30862719. 7: Selvaraj UM, Zuurbier KR, Whoolery CW, Plautz EJ, Chambliss KL, Kong X, Zhang S, Kim SH, Katzenellenbogen BS, Katzenellenbogen JA, Mineo C, Shaul PW, Stowe AM. Selective Nonnuclear Estrogen Receptor Activation Decreases Stroke Severity and Promotes Functional Recovery in Female Mice. Endocrinology. 2018 Nov 1;159(11):3848-3859. doi: 10.1210/en.2018-00600. PMID: 30256928; PMCID: PMC6203892. 8: Frenzel S, Krenn P, Heinz T, Negrin LL. Does the applied polytrauma definition notably influence outcome and patient population? - a retrospective analysis. Scand J Trauma Resusc Emerg Med. 2017 Aug 31;25(1):87. doi: 10.1186/s13049-017-0400-2. PMID: 28859678; PMCID: PMC5577783.